We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Gets Favorable Response on BsUFA III Commitments
FDA Gets Favorable Response on BsUFA III Commitments
The FDA held a virtual public meeting yesterday to discuss proposed recommendations for the reauthorization of the Biosimilar User Fee Act (BsUFA), the agency’s agreement with regulated industry on reauthorizing user fees for fiscal years 2023 through 2027, and the reception was positive.